Chemotherapy-Induced Febrile Neutropenia
"Chemotherapy-Induced Febrile Neutropenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.
| Descriptor ID |
D064146
|
| MeSH Number(s) |
C15.378.553.546.184.564.750.500
|
| Concept/Terms |
Chemotherapy-Induced Febrile Neutropenia- Chemotherapy-Induced Febrile Neutropenia
- Chemotherapy Induced Febrile Neutropenia
- Chemotherapy-Induced Febrile Neutropenias
- Febrile Neutropenia, Chemotherapy-Induced
- Febrile Neutropenias, Chemotherapy-Induced
- Neutropenia, Chemotherapy-Induced Febrile
- Neutropenias, Chemotherapy-Induced Febrile
- Drug-Induced Febrile Neutropenia
- Drug Induced Febrile Neutropenia
- Drug-Induced Febrile Neutropenias
- Febrile Neutropenia, Drug-Induced
- Febrile Neutropenias, Drug-Induced
- Neutropenia, Drug-Induced Febrile
- Neutropenias, Drug-Induced Febrile
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy-Induced Febrile Neutropenia".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy-Induced Febrile Neutropenia".
This graph shows the total number of publications written about "Chemotherapy-Induced Febrile Neutropenia" by people in this website by year, and whether "Chemotherapy-Induced Febrile Neutropenia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy-Induced Febrile Neutropenia" by people in Profiles.
-
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018 09 01; 29(9):1932-1938.
-
The effects of granulocyte colony-stimulating factor on MR images of bone marrow. Skeletal Radiol. 2019 Feb; 48(2):209-218.
-
Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One. 2018; 13(5):e0197049.
-
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
-
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 04; 19(4):497-509.
-
Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma. Pediatr Hematol Oncol. 2017 Aug; 34(5):331-342.
-
Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents. Support Care Cancer. 2018 May; 26(5):1465-1470.
-
Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies. J Oncol Pharm Pract. 2017 Mar; 23(2):121-127.
-
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. 2016 08; 57(8):1800-6.
-
Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One. 2015; 10(11):e0139851.